Letters Bevacizumab off-label

Blanket disapproval of all unlicensed indications is wrong

BMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d7726 (Published 29 November 2011) Cite this as: BMJ 2011;343:d7726
  1. Stephen J Evans, professor of pharmacoepidemiology1
  1. 1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
  1. stephen.evans{at}Lshtm.ac.uk

“Off-label” covers a variety of situations. Applications for marketing authorisations—licences that lead to a “label”—are made by companies for almost entirely commercial reasons. The company that makes bevacizumab does not apply for an authorisation …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe